Cancer
Malignant Nasopharyngeal Neoplasm
CI-CAN-00005902Explore in graph →
Top-level261 active trials1 approved drugs
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00005902Explore in graph →
Clinical trials
771 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (43)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03840421 | GP Vs PF As Induction Chemotherapy Combined with CCRT for Locoregionally Advanced Nasopharyngeal Carcinoma | active not recruiting | Phase 3 | 468 | Sun Yat-sen UniversityOTHER | 1 | Jan 13, 2025 | clinicaltrials |
| NCT06472713 | Clinical Study of Mitoxantrone Hydrochloride Liposome Combined with PD-1 Blockade in Recurrent or Metastatic NPC | recruiting | Phase 2 | 32 | Ming-Yuan ChenOTHER | 1 | Jan 13, 2025 | clinicaltrials |
| NCT06770699 |
| Tertiary Lymphoid Structures in Nasopharyngeal Carcinoma |
| active not recruiting |
| — |
| 260 |
| Jiangxi Provincial Cancer HospitalOTHER |
| 1 |
| Jan 13, 2025 |
| clinicaltrials |
| NCT06657690 | Irinotecan Liposome Combined with S-1 in PD-1/L1 Inhibitor Refractory Recurrent or Metastatic NPC | recruiting | Phase 2 | 56 | Sun Yat-sen UniversityOTHER | 1 | Jan 10, 2025 | clinicaltrials |
| NCT06763640 | Prognostic Value of TIL in Nasopharyngeal Carcinoma | enrolling by invitation | — | 216 | Jiangxi Provincial Cancer HospitalOTHER | 1 | Jan 9, 2025 | clinicaltrials |
| NCT05292027 | Neoadjuvant Chemotherapy and Low-dose Radiotherapy Sequential Concurrent Chemoradiotherapy for Locally Advanced Nasopharyngeal Carcinoma | completed | N/A | 84 | Sichuan Cancer Hospital and Research InstituteOTHER | 1 | Dec 31, 2024 | clinicaltrials |
| NCT05869227 | Maintenance Therapy With Toripalimab Combined With Capecitabine/Placebo for Recurrent and Metastatic Nasopharyngeal Carcinoma | active not recruiting | Phase 3 | 166 | XIANG YANQUNOTHER | 1 | Dec 30, 2024 | clinicaltrials |
| NCT06414577 | Irinotecan Liposomes in Combination With Nituzumab for the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma After Failure of First-Line or Higher Immunotherapy | active not recruiting | Phase 2 | 38 | XIANG YANQUNOTHER | 1 | Dec 30, 2024 | clinicaltrials |
| NCT06669611 | Nab-TPC vs GP Combined With Camrelizumab in the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma | recruiting | Phase 3 | 242 | Sun Yat-sen UniversityOTHER | 1 | Dec 30, 2024 | clinicaltrials |
| NCT06752382 | Sintilimab Combined With Bevacizumab and TP Chemotherapy in the Treatment of High Risk Locally-advanced NPC | not yet recruiting | Phase 2 | 58 | Zhejiang Cancer HospitalOTHER | 1 | Dec 30, 2024 | clinicaltrials |
| NCT06752473 | KSD-101 Therapy for Standard Treatment Failed EBV-associated Nasopharyngeal Carcinoma: an Exploratory Clinical Trial | not yet recruiting | Early Phase 1 | 10 | Kousai Bio Co., Ltd.OTHER | 0 | Dec 30, 2024 | clinicaltrials |
| NCT04028479 | The Registry of Oncology Outcomes Associated With Testing and Treatment(ROOT) | completed | — | 167 | Taproot HealthINDUSTRY | 1 | Dec 18, 2024 | clinicaltrials |
| NCT06733948 | ChemoRT With and Without Dental Stent for Taste Protection in NPC Patients | recruiting | Phase 2 | 50 | National University Hospital, SingaporeOTHER | 1 | Dec 13, 2024 | clinicaltrials |
| NCT04996758 | Toripalimab and Anlotinib Combination Treatment in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma After Failure of at Least One Line of Platinum-Based Chemotherapy (TORAL) | completed | Phase 2 | 40 | Sun Yat-sen UniversityOTHER | 1 | Dec 12, 2024 | clinicaltrials |
| NCT06719479 | A Clinical Trial to Evaluate Effect of IAE0972 Combined with Chemotherapy for R/M HNSCC or NPC(Note: It is Currently Phase II.). | not yet recruiting | Phase 2 / Phase 3 | 60 | SUNHO（China）BioPharmaceutical CO., Ltd.INDUSTRY | 0 | Dec 5, 2024 | clinicaltrials |
| NCT02460887 | The Role of Induction Gemcitabine and Cisplatin in Locoregionally Advanced Nasopharyngeal Carcinoma in the Era of IMRT | active not recruiting | Phase 3 | 236 | Sun Yat-sen UniversityOTHER | 1 | Dec 3, 2024 | clinicaltrials |
| NCT02538510 | Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer or Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery | completed | Phase 1 / Phase 2 | 50 | University of WashingtonOTHER | 1 | Nov 26, 2024 | clinicaltrials |
| NCT03813394 | Bevacizumab and Pembrolizumab Combination in Platinum-resistant Recurrent/Metastatic NPC(2018/00947) | active not recruiting | Phase 1 / Phase 2 | 48 | National University Hospital, SingaporeOTHER | 1 | Nov 22, 2024 | clinicaltrials |
| NCT06695936 | Treatment with Intensity Modulated Radiotherapy on the Change of Cognitive Function in Nasopharyngeal Carcinoma Patients: a Prospective Cohort Study | not yet recruiting | — | 329 | Sun Yat-sen UniversityOTHER | 0 | Nov 19, 2024 | clinicaltrials |
| NCT03769467 | Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC) | terminated | Phase 1 / Phase 2 | 12 | Atara BiotherapeuticsINDUSTRY | 1 | Nov 14, 2024 | clinicaltrials |
| NCT06688760 | Surgery Alone Verus Sugery Combined with Dose-reduced Radiotherapy for Newly Diagnosed Stage I Nasopharyngeal Carcinoma | recruiting | N/A | 86 | Ming-Yuan ChenOTHER | 1 | Nov 14, 2024 | clinicaltrials |
| NCT06680115 | Neoadjuvant and Adjuvant Sintilimab Combined with Chemoradiotherapy Versus Chemoradiotherapy Alone in Stage TanyN3M0 Nasopharyngeal Carcinoma | not yet recruiting | Phase 2 | 150 | First Affiliated Hospital of Guangxi Medical UniversityOTHER | 1 | Nov 8, 2024 | clinicaltrials |
| NCT06676293 | Compassionate Use of Asparaginase and Pembrolizumab Combination Theaapy for Nasopharyngeal Carcinoma | completed | N/A | 8 | Chang Gung Memorial HospitalOTHER | 1 | Nov 7, 2024 | clinicaltrials |
| NCT02113878 | Phase Ib Study of BKM120 With Cisplatin and XRT in High Risk Locally Advanced Squamous Cell Cancer of Head and Neck | completed | Phase 1 | 23 | Dana-Farber Cancer InstituteOTHER | 1 | Nov 5, 2024 | clinicaltrials |
| NCT06675214 | Under Whole-course of Immunotherapy, Gradient Fractionated RT with CCT Versus CFRT with CCT for LANPC Who Achieved PR Post Induction Chemotherapy. | recruiting | Phase 3 | 586 | Sun Yat-sen UniversityOTHER | 1 | Nov 5, 2024 | clinicaltrials |
| NCT06664983 | TPC Combined With Cadonilimab VS. TPC Alone in Anti-PD-1 Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma | active not recruiting | Phase 3 | 84 | Sun Yat-sen UniversityOTHER | 1 | Oct 30, 2024 | clinicaltrials |
| NCT04870840 | Image-guided Proton Therapy for the Treatment of Locally Advanced Unresectable Head and Neck Cancer | completed | Phase 1 | 3 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 29, 2024 | clinicaltrials |
| NCT06662929 | Arabic PRO Measures for Head and Neck Cancer Radiotherapy.(PROMs) | recruiting | — | 125 | King Saud UniversityOTHER | 1 | Oct 29, 2024 | clinicaltrials |
| NCT03809624 | Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer(PDL1x41BB) | terminated | Phase 1 | 160 | Inhibrx Biosciences, IncINDUSTRY | 1 | Oct 23, 2024 | clinicaltrials |
| NCT06572293 | Effect of Nurse-Led Individualized Follow-Up Intervention on Patients With Nasopharyngeal Carcinoma | not yet recruiting | N/A | 250 | Fujian Cancer HospitalOTHER_GOV | 0 | Oct 16, 2024 | clinicaltrials |
| NCT06463392 | Deep Learning-based sbORN Diagnostic Model | recruiting | — | 312 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Oct 1, 2024 | clinicaltrials |
| NCT06611150 | Concurrent Nab-paclitaxel with Intensity-modulated Radiation Therapy in Patients with Stage III-IVa Nasopharyngeal Carcinoma | recruiting | Phase 1 | 24 | Sun Yat-sen UniversityOTHER | 1 | Sep 27, 2024 | clinicaltrials |
| NCT04895345 | A Study of TQB2450 in Combination With Intensity-modulated Radiotherapy in Patients With Inoperable Locally Recurrent Nasopharyngeal Carcinoma | completed | Phase 2 | 25 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Sep 26, 2024 | clinicaltrials |
| NCT06614686 | U87 CAR-T in Patients With Advanced Head and Neck Tumors | recruiting | Phase 1 | 20 | Shanghai Unicar-Therapy Bio-medicine Technology Co.,LtdINDUSTRY | 1 | Sep 26, 2024 | clinicaltrials |
| NCT06611826 | GEP Combined With Radiotherapy in Non-locally Treatable Recurrent NPC | not yet recruiting | Phase 2 | 41 | Zhejiang Cancer HospitalOTHER | 0 | Sep 25, 2024 | clinicaltrials |
| NCT06612697 | Long-term Outcomes of Early-stage Nasopharyngeal Carcinoma Patients Treated with Radiotherapy Alone | active not recruiting | — | 262 | Taichung Veterans General HospitalOTHER | 1 | Sep 25, 2024 | clinicaltrials |
| NCT04220307 | A Study of a PD-1/CTLA-4 Bispecific Antibody AK104 in Patients With Metastatic Nasopharyngeal Carcinoma | completed | Phase 2 | 34 | AkesoINDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT05517135 | tReatment Individualisation By EBV stratificatiON in Nasopharyngeal Carcinoma: an Umbrella Platform Study (RIBBON-Umbrella) | recruiting | — | 1,000 | National Cancer Centre, SingaporeOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT03422536 | Ficlatuzumab w/wo Cetuximab in Patients w/Cetuximab-Resistant, Recurrent or Metastatic Head/Neck Squamous Cell Carcinoma | completed | Phase 2 | 78 | University of ArizonaOTHER | 1 | Sep 4, 2024 | clinicaltrials |
| NCT05099978 | Asian Multicenter Prospective Study of ctDNA Sequencing(A-TRAIN) | unknown | — | 506 | National Cancer Center, JapanOTHER_GOV | 8 | Sep 4, 2024 | clinicaltrials |
| NCT02875613 | Avelumab for Recurrent/Metastatic Nasopharyngeal Cancer | terminated | Phase 2 | 6 | Assuntina Sacco, M.D.OTHER | 1 | Aug 28, 2024 | clinicaltrials |
| NCT04417985 | Prognostic Utility of the Imaging and Biological Signatures in Nasopharyngeal Carcinoma | completed | N/A | 112 | Chang Gung Memorial HospitalOTHER | 0 | Aug 21, 2024 | clinicaltrials |
| NCT05892354 | Effect of Immunonutrients on Oral Mucositis in Nasopharyngeal Carcinoma Patients After Chemoradiotherapy | recruiting | N/A | 190 | First Affiliated Hospital of Guangxi Medical UniversityOTHER | 1 | Aug 7, 2024 | clinicaltrials |
| NCT06170021 | Occurrence of Radiation-induced Otitis Media in Nasopharyngeal Carcinoma Patients After Intensity Modulated Radiotherapy | unknown | — | 215 | Sun Yat-sen UniversityOTHER | 1 | Aug 6, 2024 | clinicaltrials |
| NCT06533267 | Endoscopic Surgery vs. Intensity Modulated Radiotherapy for Stage I Nasopharyngeal Carcinoma. | recruiting | N/A | 442 | Sun Yat-sen UniversityOTHER | 1 | Aug 1, 2024 | clinicaltrials |
| NCT06529562 | Surgery Plus Reduced Target Chemoradiotherapy vs Surgery Plus Reduced Dose Chemoradiotherapy for Newly Diagnosed Operable Nasopharyngeal Carcinoma. | recruiting | N/A | 384 | Ming-Yuan ChenOTHER | 1 | Jul 31, 2024 | clinicaltrials |
| NCT05638269 | A Multicentre Study on Features of the Gut Microbiota of Patients With Critical Chronic Diseases in China | unknown | — | 12,000 | Zhujiang HospitalOTHER | 1 | Jul 29, 2024 | clinicaltrials |
| NCT06523933 | Distribution of Bacteria in OME After Radiotherapy For NPC. | unknown | — | 234 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Jul 26, 2024 | clinicaltrials |
| NCT05193617 | Penpulimab Combined With GP ± Anlotinib as Neoadjuvant Therapy in Locoregionally Advanced Nasopharyngeal Carcinoma | active not recruiting | Phase 2 | 104 | Sun Yat-sen UniversityOTHER | 1 | Jul 23, 2024 | clinicaltrials |
| NCT06516133 | Online Adaptive Radiotherapy for Nasopharyngeal Carcinoma(OART) | recruiting | Phase 3 | 494 | Sun Yat-sen UniversityOTHER | 1 | Jul 23, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Jan 13, 2025source: clinicaltrials